The Mobilise-D consortium and the Critical Path Institute (C-Path) are thrilled to announce the signing of a collaboration agreement, which will be an important step forward in achieving lasting impact.
C-Path is an independent nonprofit, public-private partnership with the U.S. Food and Drug Administration (FDA). C-Path orchestrates the development of actionable solutions through an innovative, collaborative approach to the sharing of data and expertise. Such consensus provides the mechanism to generate the necessary confidence to assure the adoption of medical product development solutions by sponsors and regulators. Mobilise-D focuses on digital assessment of mobility, which is an important technology for evaluating how patients with various diseases are functioning in their own environments. These tools can open an entirely new way of showing whether treatments are working to help patients regain or maintain their independence and could have profound impact on developing new treatments for many diseases. The collaboration between Mobilise-D and C-Path brings together two key leading organizations in this important effort.
The collaboration agreement is part of the Mobilise-D consortium strategic collaboration agreements policy. Through this policy, Mobilise-D aims to extend the outreach of the work and results of the consortium by working with other scientific and research groups, transitioning to sustainability through enhanced communication and long-lasting relationships.
Professor Lynn Rochester from Newcastle University – the academic coordinator of the Mobilise-D consortium – says: “We are delighted to formalize our collaboration with C-Path who share our ambition to develop the next generation digital tools to enhance research and ultimately patient care. We have already learnt significantly from our interactions with C-Path, and we are looking forward to our continued efforts to drive forward important insights that not only inform our work but that of the wider community.”
Dr Diane Stephenson – the Executive Director of the Critical Path Institute – adds: “Critical Path Institute and Mobilise-D collaborative partnership shares a common vision that digital health technologies will be accepted for use in clinical trials in diseases that impact physical function and mobility, such as Parkinson’s disease. By aligning across global public private partnerships, our path to achieving success promises to be streamlined and more efficient.”
Both Mobilise-D and C-Path have common themes and objectives that will form the basis for potential collaboration. Examples include:
- Sharing learning from regulatory interactions for digital health technologies
- Advancing implementation of digital health technology tools
- Verification and validation of digital tools
- Developing patient-centred outcome measurements
- Consensus data standards for prospective digital health technologies studies and data sharing
- Sensor data integration from distinct devices
- Development of open source platforms
Mobilise-D and C-Path will work towards developing these collaborative areas to increase the impact of their work and for the benefit of their stakeholders and especially patients.
So far, the Mobilise-D consortium has signed collaboration agreements with IDEA-FAST, NEURONET, Cure Parkinson UK, and VOICE GLOBAL.
